We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Coherus BioSciences (CHRS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Coherus BioSciences is one of 901 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CHRS is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CHRS's full-year earnings has moved 10.64% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, CHRS has moved about 19.77% on a year-to-date basis. At the same time, Medical stocks have gained an average of 1.95%. This means that Coherus BioSciences is outperforming the sector as a whole this year.
Looking more specifically, CHRS belongs to the Medical - Biomedical and Genetics industry, a group that includes 385 individual stocks and currently sits at #70 in the Zacks Industry Rank. Stocks in this group have gained about 1.51% so far this year, so CHRS is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CHRS as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Coherus BioSciences (CHRS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Coherus BioSciences is one of 901 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CHRS is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CHRS's full-year earnings has moved 10.64% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, CHRS has moved about 19.77% on a year-to-date basis. At the same time, Medical stocks have gained an average of 1.95%. This means that Coherus BioSciences is outperforming the sector as a whole this year.
Looking more specifically, CHRS belongs to the Medical - Biomedical and Genetics industry, a group that includes 385 individual stocks and currently sits at #70 in the Zacks Industry Rank. Stocks in this group have gained about 1.51% so far this year, so CHRS is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CHRS as it looks to continue its solid performance.